Genmab — April 2020

[E_L]

"The study seeks to determine the recommended Phase 2 dose in patients with advanced NSCLC.[5] Enrollment into the Part 2 dose expansion cohorts is ongoing" https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer

[Hugininvest]

PS! Hos Genmab angives det at fase 2 er igang

[Hugininvest]

Men det samme siger JNJ jo, så CT er ikke opdateret

[Bulder]

Genmab siger det er i fase I/II. Part 2 er 2. del af fase 1

[Bulder]

For mig lyder det som en lidt tidlig submission, da de end ikke har fundet RP2D.

[GeorgeBest]

submission i slutning af året...

[GeorgeBest]

kan de nå at få nok evidens til slutning af året?

[Hugininvest]

Genmab: JNJ-61186372 is being investigated in Phase II clinical studies to treat non-small cell lung cancer (NSCLC). Lidt forvirrende, men konklusionen er at der er tro på det.

[Bulder]

åbenbart. Men et oplagt spm til Winkel for at få lidt klarhed.

[GeorgeBest]

enig, hvorfor skulle de ellers nævnte det på CC

[Sukkeralf]

Det står jo fint beskrevet i det link E L smed angående BTD - det er i EGFR Egon 20 mutationer, hvor der ikke er nogen godkendte terapier

[Sukkeralf]

Exon

[Bulder]

ha ha

[Bulder]

så det er unmet medical need

[Sukkeralf]

Jeps

[GeorgeBest]

der venter potentielt 10% royalties af en ny blockbuster. whats not to like

[Bulder]

mange bække små

[E_L]

it is also a potential SC candidate , according to Halozyme "In December, Janssen selected for development with ENHANZE the targets EGFR and cMET on an exclusive basis as part of the bispecific antibody (JNJ-61186372), which is being studied in solid tumors."

[Bulder]

Thx E L

[E_L]

and it looks like they named it 'amivantamab'..... Also, Yuhan Corporation in Korea apparantly received it's first milestone for Lazertinib from Janssen this month, for results in the the combination therapy with JNJ-372... to be continued...